J&J unit Janssen Biotech has entered an agreement with Pharmacyclics, Inc. to jointly develop and market the anti-cancer compound, PCI-32765. Several Phase I and II studies are ongoing across a panel of B-cell malignancy disorders, including chronic lymphocytic leukemia, mantle cell lymphoma, and diffuse large B-cell lymphoma. The companies have entered into a worldwide 50/50 profit-loss agreement, sharing development and commercialization activities. Janssen has made an upfront payment of ...